EMA amends market approval rules based on pharmacovigilance experience

Published: 18-Mar-2014
Regulatory

Reforms cover submission of paediatric medicine studies, among other things


Fresh changes have been made by the European Medicines Authority (EMA) to its market authorisation procedures based on experience gained from the implementation of new European Union (EU) pharmacovigilance rules.

The reforms cover, for instance, the submission of paediatric medicine studies, environmental risk assessments and amendments of deadlines for delivering marketing authorisation conditions.

  • Companies:
  • EMA European Medicines Agency
See more

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Read more
Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency

Trending Articles

  1. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  4. Ametek Mocon achieves accreditation for analytical testing laboratory Ametek Mocon, provider of instruments and services for testing, measuring and analysing a variety of gases, has achieved ISO/IEC 17025 accreditation for its Minneapolis analytical testing laboratory
  5. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Distribution

Moderna receives positive opinion from the EMA for Spikevax

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Regulatory

EMA celebrates 25 years of regulatory management

The EMA was founded in January 1995
Regulatory

EMA publishes draft guideline on quality requirements for DDCs

The latest document focuses on combinations of medicinal products and medical devices
Regulatory

GMP inspection in Bulgaria and Cyprus now on par with US

A mutual recognition agreement between the EU and the US regulatory bodies aims to encompass all EU member states, now standing at 24 of the 28
Regulatory

Brexit update: UK Inspection Reports and GMP Certificates

The ECA Academy sheds light on the latest Brexit guidance documents released by the European Medicines Agency
Regulatory

Poland and Slovenia join EU-US mutual recognition agreement for inspections

GMP drug plant inspections conducted by health authorities in Poland and Slovenia will now be accepted by the US FDA
Subscribe now